StockData
Prime Medicine, Inc. logo

Prime Medicine, Inc. (PRME) stock

PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$3.84−0.35 (-8.35%)

Close on Nov 17, 2026Market cap $696.49MP/E –Yield –

Prime Medicine price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Prime Medicine's price to sales ratio was 138.2× on Apr 30, 2026, against 76.1× a year earlier.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 2026138.2×+33.5
2025Dec 31, 2025104.7×−374.1
2024Dec 31, 2024478.7×–

More Prime Medicine figures

See a number that looks wrong?